Glioblastoma (GBM) is the most common malignant primary brain tumor with an exceedingly poor prognosis despite multimodality treatment.1,2 It represents a heterogeneous entity with an expansive molecular and mutational landscape.3 The recently updated World Health Organization (WHO) classifications have now incorporated some of the new molecular advances in their categorization and notably distinguishes GBM by isocitrate dehydrogenase (IDH) mutation status.4 Significant advances in molecular and genetic techniques have allowed for the detailed analysis of genomic alterations in GBM. Here, IDH2 is linked to glioblastoma.